Most for-profit hospital companies seem poised to deliver their healthiest performance in years.

After suffering through a painful downturn through much of 2003 and 2004, the hospital industry has tried to mend some of its nastiest problems -- particularly bad debt from the uninsured -- and, in turn, has given investors fresh hope that a full-scale recovery is finally on the way. To be sure, the group kicked off 2005 with a bang, delivering pleasant earnings surprises that have pushed hospital stocks up more than 30% so far this year. Now, however, the sector must carry that momentum forward -- without the help it received earlier from the flu -- to prove its overall health.

Credit Suisse First Boston analyst Glen Santangelo believes that at least some of the companies can.

"We have a generally favorable view of the sector," Santangelo writes. "Continued improvement on the cost side -- particularly salaries and bad-debt expense -- combined with easy comparisons, gives us confidence in our estimates, with the potential for upside."

Although Santangelo recently initiated coverage of the group with a conservative market-weight rating, due primarily to valuation concerns, he points to several individual players as likely winners with still more room to run.

Industry giant


(HCA) - Get Report

ranks high among his picks. Even after soaring more than 40% this year, he notes, HCA shares still have yet to reach their average five-year valuation. And he, for one, is convinced that the stock deserves more.

"Based on our analysis, the current consensus estimates conservatively anticipate a modest recovery in the operating fundamentals of the company," Santangelo writes. "We believe this conservative outlook has created an attractive risk/reward scenario for investors."

Santangelo is looking for HCA to beat full-year profit expectations of $3.17 a share. Thus, he has established a $66 target price for the stock.

The shares, which fell 13 cents on Friday, currently fetch just $56.54 instead.

Santangelo also likes



, a rural hospital operator. He believes the company will benefit from not only improving industry fundamentals but also its own expansion through its recent purchase of Province. Finally, he recommends

Health Management Associates


despite concerns about the company's recent underperformance and its ability to keep raising hospital prices going forward.

"We are not completely dismissing the concerns regarding the company's billing practices, but take comfort in the company's very public denial and the time that has elapsed since the original concerns surfaced in late 2003," Santangelo writes. Meanwhile, "we believe that the fundamentals are poised to turn in the second half of calendar 2005 and that the combination of the recent acquisitions and the easier comparisons will re-accelerate earnings growth."

HMA, which fell 28 cents to $25.90 on Friday, has trailed some of its peers with an 18% gain over the past year.

UBS analyst Kenneth Weakley -- who first raised HMA pricing concerns after exposing the aggressive pricing games at


(THC) - Get Report

-- offers a contrasting view. While he prefers HCA over his other neutral-rated hospital stocks, he recommends selling both LifePoint and HMA outright.

Notably, Weakley sees little reason to celebrate LifePoint's recent acquisition.

"From an investment perspective, our concerns relate to LifePoint's ability to realize an accretion to returns over the long run with the addition of Province," Weakley writes. "We remain concerned that LifePoint's willingness to buy Province may signal that its core assets are fully mature."

LifePoint's stock dropped 29 cents to $50.26 on Friday but has rocketed more than 35% over the past year.

Meanwhile, Weakely has come down even harder on HMA. Not only does HMA charge high prices that may prove unsustainable, he notes, but the company has seen its performance deteriorate already.

"HMA's earnings growth has lagged the group in recent quarters," he writes. And "we expect this trend to continue."

Weakley remains bearish on Tenet as well. He believes the company's legal issues remain "far from settled" and that its operations continue to be "very much challenged" in the meantime.

Jeff Villwock, a Caymus Partners analyst who conducts research on behalf of the Tenet Shareholder Committee -- a group long critical of company management -- tends to agree. Villwock believes the company's operational problems, in particular, will prove especially difficult to solve.

He says that Tenet's pricing is weak and its volumes are soft. Thus, he believes the company will be forced to sell even more assets -- perhaps as many as 15 hospitals -- by the time the year comes to an end.

"It will become obvious, as they go through the summer, which hospitals don't have a chance," Villwock says. "And they'll want to write those off by Dec. 31, so they can have another -- third -- fresh start."

Tenet's stock slipped a penny to $12.23 and, unlike the rest of the group, has lost some ground since this time last year.

To be fair, Villwock is more upbeat about the hospital industry in general. He believes that bad debt expense, while still high, has at least stabilized. He also expects most hospitals to report decent volume growth, especially for their lucrative outpatient business, going forward.

"Industrywide, I think hospitals will do a little better than they have -- and possibly even slightly better than anticipated," he says. "But Tenet, I don't think, is going to be quite so lucky."